Summary of COVID-19 BI 764198 studies

1. Ware et al., TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial

129 patient BI 764198 late treatment RCT: 117% higher mortality (p=0.18), 12% higher progression (p=0.84), and 42% worse recovery (p=0.48).
RCT 129 hospitalized COVID-19 patients requiring non-invasive oxygen support showing no benefit and potential harm with BI 764198 (TRPC6 inhibitor). The study was terminated early due to lack of efficacy and an imbalance of fatal events (11 deaths vs 5 deaths in placebo group). Patients receiving BI 764198 had longer hospitalizations (+3.4 days), longer time to recovery, and longer oxygen use duration compared to placebo.
Apr 2023, Thorax, https://thorax.bmj.com/lookup/doi/10.1136/thorax-2022-219668, https://c19p.org/ware2